Sinovac Biotech has upped its offer to de-list from Nasdaq almost 17 months after it first tried to go private, in a deal that values the firm at around $401.8 million. But it could still have its work cut out to get the deal done given ongoing pricing disputes and bribery concerns.
According to a filing to the US Securities and Exchange Commission SEC on Monday, parent entity Sinovac Cayman Limited will acquire the biopharmaceutical products provider for a cash consideration of $7 per common share. A consortium comprising Yin Weidong, chairman, president and chief executive officer of Sinovac Biotech, SAIF Softbank Asia Infrastructure Fund Partners, C-Bridge Capital, Advantech...
¬ Haymarket Media Limited. All rights reserved.
